The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
about
Hepatitis C virus: A time for decisions. Who should be treated and when?Imaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical ApproachVitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirinAlcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infectionsHCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeSelective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsActivins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy.The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary reportResults from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation ProgramCancers attributable to infections among adults with HIV in the United States.Health state utilities associated with attributes of treatments for hepatitis C.Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity."Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment.Public health clinic-based hepatitis C testing and linkage to care in Baltimore.The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United StatesEmergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.Characterizing Failure to Establish Hepatitis C Care of Baby Boomers Diagnosed in the Emergency Department.Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Sofosbuvir (Sovaldi) for the treatment of hepatitis C.Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents.Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C.Engagement in the Hepatitis C Care Cascade Among Homeless Veterans, 2015.Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion.The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand.High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion.For patients with rheumatic disease and hepatitis C infection: the end of interferon.Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014.The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment.Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C.Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).'Sussing that doctor out.' Experiences and perspectives of people affected by hepatitis C regarding engagement with private general practitioners in South Australia: a qualitative study.
P2860
Q26768274-D6D47383-B4DD-450A-AD8C-322958134BC2Q26771433-817347B3-D03C-4C83-8A7C-DDA67C141433Q26784321-6304D1AD-DA14-4852-94F0-CA504403D72DQ28070280-777F7B6F-869E-451B-BDE5-1E796E894923Q31012317-56D63D82-61A2-42E3-A4FA-F8A20C8DB899Q33797817-04A4F4D9-C088-437A-A03B-25BE2C35FA1EQ33858322-ED81B01C-76E6-4DE8-A121-52A575164B03Q34028307-B765F6E6-76DE-4CBC-A0EB-165328488E82Q34735072-E9AB9934-0F46-4E20-A2A2-C456732E8BA5Q35563500-7F25E312-6175-40CF-A2FB-773DE75CC037Q35593482-B48F805A-AB79-4C17-B41B-CA14C4481FEEQ35639889-3464CF18-6257-4D3D-B7C3-4C49E8810496Q35674832-92061E7A-1684-45D7-942B-467AEFF50A5FQ35752660-54299314-ECD8-419F-AD0E-715C15757C21Q36259445-5FA6CFED-D34E-484D-86E8-8CA26A787E2AQ36285092-2B37FAF7-5F2D-4E37-9CB1-62E44E595141Q36406176-15DB0BE6-8E11-4CF8-986E-C6DEB7A5C617Q36595767-429B59A8-2032-4C32-B580-4CB305210D97Q36813466-EF38C2A4-D72E-46DD-A8E2-8A7ACD0B67FBQ36849533-064B798D-60B1-4F40-ADFB-15235B5BD00BQ37018850-6FD51388-0C7F-483C-AE47-970754553DC2Q37220279-DCE7B423-76FF-458A-B86F-9E05C2C6A3E3Q37543670-4A6FC93D-1870-4D26-9A3A-E39964C0AE2FQ37578288-FB5F4592-E764-4275-ACC4-C7AE4458F67EQ38219424-D53F2924-21F3-4DB9-ADDF-E462E9861A39Q38408888-174C34BA-342A-4FE2-97F6-2B2F900A7529Q38947375-A885D3E4-7477-48EC-BF96-43064D9911C9Q38991902-4B32C985-366D-4D15-9B9D-F743ADD645C7Q40091374-34A3309B-99E1-4D15-B4D2-8D599286B286Q40219302-1C78C524-16A9-4910-AA8D-FDB668CF5409Q40561879-BD074DDC-2F0E-4C85-BB09-D7EB07F00D71Q40649732-5F3A794B-4D03-414A-967F-B6176CCC4753Q40873258-F070AB13-2037-41A7-82F3-3D5EFFF23379Q40921653-4B1272EE-BADD-4E8F-A6E7-196EA8B25A0DQ40934454-BAC68F1E-9C31-4B36-9847-CBC9BBC5F910Q40966047-D4FD8E25-3973-47DF-BBFE-69DF341E5A12Q41463702-AAE4AB23-8F9A-4A64-AB0D-4DBE041A3F4FQ41929182-9C4DCE1E-E6D3-4C8F-9FE6-097B8CDBDE2FQ42220208-86E1AF58-0021-4E9B-93B9-A5C53A59D967Q47156419-4156B3DD-1B94-4E6B-9886-75517039AF4F
P2860
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The new paradigm of hepatitis ...... therapies into best practices.
@en
The new paradigm of hepatitis ...... therapies into best practices.
@nl
type
label
The new paradigm of hepatitis ...... therapies into best practices.
@en
The new paradigm of hepatitis ...... therapies into best practices.
@nl
prefLabel
The new paradigm of hepatitis ...... therapies into best practices.
@en
The new paradigm of hepatitis ...... therapies into best practices.
@nl
P2093
P2860
P921
P356
P1476
The new paradigm of hepatitis ...... therapies into best practices.
@en
P2093
A H Litwin
D L Thomas
D R Church
I M Jacobson
P2860
P304
P356
10.1111/JVH.12173
P577
2013-11-01T00:00:00Z